Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at Zacks Research boosted their Q1 2026 EPS estimates for shares of Alkermes in a research report issued on Tuesday, July 1st. Zacks Research analyst R. Department now expects that the company will post earnings of $0.39 per share for the quarter, up from their prior forecast of $0.36. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share.
A number of other research firms have also weighed in on ALKS. HC Wainwright reiterated a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Needham & Company LLC started coverage on shares of Alkermes in a report on Wednesday, May 28th. They issued a "buy" rating and a $45.00 target price on the stock. Wall Street Zen cut shares of Alkermes from a "strong-buy" rating to a "buy" rating in a report on Monday, May 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. Finally, Royal Bank Of Canada increased their target price on Alkermes from $39.00 to $40.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $40.00.
Read Our Latest Research Report on Alkermes
Alkermes Price Performance
Shares of NASDAQ:ALKS traded down $0.25 during trading on Wednesday, reaching $28.75. The company had a trading volume of 1,122,189 shares, compared to its average volume of 1,737,488. Alkermes has a fifty-two week low of $22.90 and a fifty-two week high of $36.45. The stock's fifty day moving average price is $30.12 and its 200 day moving average price is $30.89. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 13.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.30% and a return on equity of 27.52%. The business had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. During the same quarter in the prior year, the firm posted $0.43 earnings per share. The company's revenue for the quarter was down 12.6% compared to the same quarter last year.
Hedge Funds Weigh In On Alkermes
Several large investors have recently added to or reduced their stakes in ALKS. Voya Investment Management LLC grew its holdings in Alkermes by 6.0% in the 1st quarter. Voya Investment Management LLC now owns 477,183 shares of the company's stock valued at $15,757,000 after buying an additional 27,136 shares during the period. Strs Ohio acquired a new stake in shares of Alkermes in the first quarter worth approximately $1,403,000. Acadian Asset Management LLC grew its holdings in Alkermes by 2,422.0% in the first quarter. Acadian Asset Management LLC now owns 881,827 shares of the company's stock valued at $29,100,000 after purchasing an additional 846,861 shares during the period. Intech Investment Management LLC grew its holdings in Alkermes by 25.6% in the first quarter. Intech Investment Management LLC now owns 85,564 shares of the company's stock valued at $2,825,000 after purchasing an additional 17,413 shares during the period. Finally, Bayforest Capital Ltd increased its position in Alkermes by 105.2% during the first quarter. Bayforest Capital Ltd now owns 9,270 shares of the company's stock worth $306,000 after purchasing an additional 4,752 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, SVP Christian Todd Nichols sold 3,334 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the sale, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. This trade represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.40% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
